Colitis ulcerative

47 trials 13 recruiting MedDRA PT
47 Registered trials
13 Recruiting
24 Unique sponsors
21 Unique IMPs
37 Commercial trials
Drug classes (ATC)
— ATC code not specified 37
L Oncology (ATC L) 8
A Gastroenterology (ATC A) 1
V Various (ATC V) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 12 substances
Monoclonal antibody (humanized) 3 substances
Monoclonal antibody (human) 2 substances
JAK inhibitor 2 substances
Monoclonal antibody (immune, humanized) 1 substance
Monoclonal antibody (chimeric) 1 substance
Phase III: 14 Phase II/III: 1 Phase II: 10 Phase IV: 4 Phase I: 4 Phase I (Other): 10 Other: 4

Filter these 47 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 47 trials

Phase III

14 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    UPADACITINIB
    2022-501788-41-00 11 countries 2023 n=46
    Recruiting
  • AbbVie Deutschland GmbH & Co. KG Commercial
    UPADACITINIB
    2023-505699-31-00 20 countries 2017 n=167
    Ended
  • AbbVie Deutschland GmbH & Co. KG Commercial
    RISANKIZUMAB
    2023-506994-36-00 19 countries 2018 n=544
    Ended
  • Abivax Commercial
    OBEFAZIMOD
    2022-500535-36-01 13 countries 2023 n=258
    Ended
  • Abivax Commercial
    OBEFAZIMOD
    2022-500536-11-01 14 countries 2023 n=322
    Ended
  • Eli Lilly & Co. Commercial
    MIRIKIZUMAB
    2022-502183-20-00 7 countries 2024 n=30
    Ended
  • Faes Farma S.A. Commercial
    MESALAZINE
    2023-509606-30-00 7 countries 2024 n=406
    Recruiting
  • Sanofi-Aventis Recherche & Developpement Commercial
    DUVAKITUG
    2025-521035-37-00 15 countries 2026 n=499
    Recruiting
  • Sanofi-Aventis Recherche & Developpement Commercial
    DUVAKITUG
    2025-521038-27-00 15 countries n=209
    Pending
  • Abivax Academic
    OBEFAZIMOD
    2022-500535-36-00 6 countries n=165
    Not authorised
  • Abivax Academic
    OBEFAZIMOD
    2022-500536-11-00 6 countries n=167
    Not authorised
  • Abivax Academic
    OBEFAZIMOD
    2022-500537-84-00 6 countries n=339
    Not authorised
  • Centre Medico Chirurgical Ambroise Pare Hartmann Academic
    INFLIXIMAB
    2023-508584-72-00 1 country 2024 n=130
    Ended
  • Medical University Of Gdansk Academic
    INFLIXIMAB; OXYGEN; USTEKINUMAB; VEDOLIZUMAB
    2023-507450-32-00 1 country n=40
    Ended

Phase II/III

1 trial
  • Universitaetsklinikum Schleswig-Holstein AöR Academic
    NICOTINAMIDE
    2024-510807-13-00 1 country 2024 n=459
    Recruiting

Phase II

10 trials
  • AbbVie Deutschland GmbH & Co. KG Commercial
    ABBV-668
    2022-501263-41-00 3 countries 2023 n=36
    Ended
  • AbbVie Deutschland GmbH & Co. KG Commercial
    ADALIMUMAB; LUTIKIZUMAB
    2023-505678-14-00 18 countries 2024 n=96
    Recruiting
  • Odyssey Therapeutics Inc. Commercial
    OD-07656 HYDROCHLORIDE; VEDOLIZUMAB
    2024-520201-39-00 7 countries 2025 n=70
    Recruiting
  • Sanofi-Aventis Recherche & Developpement Commercial
    BALINATUNFIB
    2025-520705-12-00 12 countries 2025 n=178
    Recruiting
  • Sanofi-Aventis Recherche & Developpement Commercial
    BALINATUNFIB
    2025-522511-42-00 14 countries n=131
    Pending
  • Sanofi-Aventis Research & Development Commercial
    ECLITASERTIB
    2022-500290-14-01 11 countries 2023 n=129
    Ended
  • Takeda Development Center Americas Inc. Commercial
    ZASOCITINIB
    2023-506769-67-00 13 countries 2024 n=200
    Ended
  • Takeda Development Center Americas Inc. Commercial
    ZASOCITINIB
    2024-518914-18-00 14 countries 2025 n=113
    Recruiting
  • Vedanta Biosciences Inc. Commercial
    BACILLI, CLUSTER XVIII, STRAIN RELATIVE THOMASCLAVELIA SP000508865, LIVE, CLOSTRIDIA, CLUSTER XIVA, STRAIN RELATIVE HUNGATELLA EFFLUVII, LIVE, CLOSTRIDIA, CLUSTER XIVA, STRAIN RELATIVE BLAUTIA COCCOIDES, LIVE, CLOSTRIDIA, CLUSTER XIVA, STRAIN RELATIVE ANAEROSTIPES HOMINIS, LIVE, CLOSTRIDIA, CLUSTER XIVA, STRAIN RELATIVE ENTEROCLOSTER ASPARAGIFORMIS, LIVE, BACILLI, CLUSTER XVIII, STRAIN RELATIVE THOMASCLAVELIA RAMOSUM, LIVE, CLOSTRIDIA, CLUSTER XIVA, STRAIN RELATIVE MURICOMES SP000509105, LIVE, CLOSTRIDIA, CLUSTER XIVA, STRAIN RELATIVE CLOSTRIDIUM_AP SP000509125, LIVE, CLOSTRIDIA, CLUSTER XIVA, STRAIN RELATIVE EISENBERGIELLA PORCI, LIVE, CLOSTRIDIA, CLUSTER XIVA, STRAIN RELATIVE ENTEROCLOSTER PACAENSE, LIVE, CLOSTRIDIA, CLUSTER XIVA, STRAIN RELATIVE EISENBERGIELLA TAYI, LIVE, CLOSTRIDIA, CLUSTER XIVA, STRAIN RELATIVE CLOSTRIDIUM_Q SYMBIOSUM, LIVE, CLOSTRIDIA, CLUSTER XIVA, STRAIN RELATIVE ENTEROCLOSTER BOLTEAE, LIVE, CLOSTRIDIA, CLUSTER XIVA, STRAIN RELATIVE SELLIMONAS INTESTINALIS, LIVE, CLOSTRIDIA, CLUSTER IV, STRAIN RELATIVE FLAVONIFRACTOR PLAUTII, LIVE, CLOSTRIDIA, CLUSTER IV, STRAIN RELATIVE ANAEROTRUNCUS COLIHOMINIS, LIVE
    2024-512558-40-00 6 countries 2023 n=74
    Ended
  • Universitaetsklinikum Heidelberg AöR Academic
    AUTOLOGOUS REGULATORY T-CELLS WITH AN IMMUNOPHENOTYPE OF CD4+CD25HI/+FOXP3+
    2025-520628-11-00 1 country n=30
    Pending

Phase IV

4 trials
  • Eli Lilly & Co. Commercial
    MIRIKIZUMAB
    2025-522362-78-00 5 countries n=16
    Pending
  • Amsterdam UMC Stichting Academic
    VEDOLIZUMAB
    2024-514740-82-00 1 country 2025 n=278
    Recruiting
  • Amsterdam UMC Stichting Academic
    OXYGEN
    2024-515278-28-00 1 country 2024 n=24
    Ended
  • Groupe D'etude Therapeutique Des Affections Inflammatoires Du Tube Digestif Academic
    ADALIMUMAB
    2023-507256-76-00 1 country 2020 n=238
    Recruiting

Phase I

4 trials
  • Chong Kun Dang Pharmaceutical Corp. Commercial
    IMP not specified
    2025-522345-21-00 1 country 2025 n=213
    Ended
  • Granite Bio AG Commercial
    IMP not specified
    2023-507547-11-00 1 country 2024 n=112
    Recruiting
  • Microbiotica Limited Commercial
    IMP not specified
    2023-507376-50-00 4 countries 2024 n=46
    Ended
  • Pfizer Inc. Commercial
    IMP not specified
    2023-507354-32-00 1 country 2024 n=55
    Ended

Phase I (Other)

10 trials
  • Abivax Commercial
    IMP not specified
    2023-509226-21-00 1 country 2024 n=24
    Ended
  • EnteroTarget ApS Commercial
    IMP not specified
    2023-510335-11-00 1 country 2025 n=6
    Ended
  • Enthera S.r.l. Commercial
    IMP not specified
    2023-507340-36-00 4 countries 2024 n=40
    Ended
  • Faes Farma S.A. Commercial
    IMP not specified
    2024-514748-10-00 1 country 2024 n=34
    Ended
  • Faes Farma S.A. Commercial
    IMP not specified
    2024-517107-37-00 1 country 2024 n=60
    Ended
  • Genentech Inc. Commercial
    IMP not specified
    2024-516287-29-00 1 country 2025 n=24
    Recruiting
  • Granite Bio AG Commercial
    IMP not specified
    2025-524328-24-00 1 country 2026 n=40
    Recruiting
  • Liveome Inc. Commercial
    IMP not specified
    2024-514520-16-00 1 country n=8
    Pending
  • Pfizer Inc. Commercial
    ETRASIMOD ARGININE
    2023-504411-32-00 1 country 2023 n=16
    Ended
  • Pfizer Inc. Commercial
    IMP not specified
    2023-505603-23-00 1 country 2024 n=12
    Ended

Other

4 trials
  • Sanofi-Aventis Recherche & Developpement Commercial
    IMP not specified
    2025-521073-13-00 1 country 2025 n=15
    Ended
  • Sun Pharmaceutical Industries Limited Commercial
    IMP not specified
    2024-512770-10-00 1 country 2024 n=50
    Ended
  • Sun Pharmaceutical Industries Limited Commercial
    IMP not specified
    2024-512771-12-00 1 country 2024 n=32
    Ended
  • Sun Pharmaceutical Industries Limited Commercial
    IMP not specified
    2024-512773-27-00 1 country 2024 n=54
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Abivax Commercial 6 Phase I (Other), Phase III 0
Sanofi-Aventis Recherche & Developpement Commercial 5 Other, Phase II, Phase III 2
AbbVie Deutschland GmbH & Co. KG Commercial 5 Phase II, Phase III 2
Pfizer Inc. Commercial 3 Phase I, Phase I (Other) 0
Sun Pharmaceutical Industries Limited Commercial 3 Other 0
Faes Farma S.A. Commercial 3 Phase I (Other), Phase III 1
Granite Bio AG Commercial 2 Phase I, Phase I (Other) 2
Takeda Development Center Americas Inc. Commercial 2 Phase II 1
Eli Lilly & Co. Commercial 2 Phase III, Phase IV 0
Amsterdam UMC Stichting Academic 2 Phase IV 1
Chong Kun Dang Pharmaceutical Corp. Commercial 1 Phase I 0
Microbiotica Limited Commercial 1 Phase I 0
EnteroTarget ApS Commercial 1 Phase I (Other) 0
Enthera S.r.l. Commercial 1 Phase I (Other) 0
Genentech Inc. Commercial 1 Phase I (Other) 1
Liveome Inc. Commercial 1 Phase I (Other) 0
Odyssey Therapeutics Inc. Commercial 1 Phase II 1
Sanofi-Aventis Research & Development Commercial 1 Phase II 0
Vedanta Biosciences Inc. Commercial 1 Phase II 0
Universitaetsklinikum Schleswig-Holstein AöR Academic 1 Phase II/III 1
New trials by year
2020
1
2023
7
2024
18
2025
8
2026
2
← All indication landscapes